PT 00114

Drug Profile

PT 00114

Alternative Names: PT 00114

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Protagenic Therapeutics
  • Developer Charles River Laboratories; Protagenic Therapeutics
  • Class Antidepressants; Peptides
  • Mechanism of Action Corticotropin-releasing factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Anxiety disorders; Depressive disorders; Impulse control disorders; Neurodegenerative disorders; Opioid abuse

Most Recent Events

  • 05 Oct 2017 Pharmacodynamics data from a preclinical trial in Anxiety disorders and Depressive disorders released by Protagenic Therapeutics
  • 28 Sep 2017 Preclinical trials in Anxiety disorders in Finland (SC), before September 2017
  • 28 Sep 2017 Preclinical trials in Depressive disorders in Finland (SC), before September 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top